Cyclohexanol → 4-[1-(4-Methanesulfonyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy]-piperidine-1-carboxylic acid cyclohexyl ester

HRID 1958425

반응식

HRID 1958425 반응식
[C:1](N1C=CN=C1)(N1C=CN=C1)=[O:2].[CH:13]1([OH:19])[CH2:18][CH2:17][CH2:16][CH2:15][CH2:14]1.Cl.[CH3:21][S:22]([C:25]1[CH:30]=[CH:29][C:28]([N:31]2[C:35]3=[N:36][CH:37]=[N:38][C:39]([O:40][CH:41]4[CH2:46][CH2:45][NH:44][CH2:43][CH2:42]4)=[C:34]3[CH:33]=[N:32]2)=[CH:27][CH:26]=1)(=[O:24])=[O:23].C(N(CC)CC)C>CN(C=O)C>[CH:13]1([O:19][C:1]([N:44]2[CH2:45][CH2:46][CH:41]([O:40][C:39]3[N:38]=[CH:37][N:36]=[C:35]4[N:31]([C:28]5[CH:29]=[CH:30][C:25]([S:22]([CH3:21])(=[O:23])=[O:24])=[CH:26][CH:27]=5)[N:32]=[CH:33][C:34]=34)[CH2:42][CH2:43]2)=[O:2])[CH2:18][CH2:17][CH2:16][CH2:15][CH2:14]1

참가 물질

6

실험 절차

Carbonyldiimidazole (0.28 mmol, 46 mg), and cyclohexanol (0.28 mmol, 34 μL) were dissolved in DMF (2 mL) and stirred for 30 minutes at room temperature. Then, 1-(4-Methanesulfonyl-phenyl)-4-(piperidin-4-yloxy)-1H-pyrazolo[3,4-d]pyrimidine hydrochloride salt (0.16 mmol, 60 mg) and triethylamine (0.84 mmol, 118 μL) were added and continued to stir at 60° C. for 24 hours. The reaction mixture was quenched with water followed by an extraction with ethylacetate. Removal of organic solvents in vacuo and purification by HPLC provided compound A63 as a white solid. 1H NMR (400 MHz, CDCl3) δ (ppm): 8.67 (s, 1H); 8.61 (d, 2H); 8.26 (s, 1H); 8.11 (d, 2H); 5.62 (h, 1H); 4.71 (h, 1H); 3.91 (m, 2H); 3.38 (m, 2H); 3.10 (s, 3H); 2.10 (m, 2H); 1.87 (m, 4H), 1.65 (m, 6H); 1.28 (m, 2H). LCMS (ESI), m/z 500.4 (MH+, 100%)

후처리

  1. stirringto stir at 60° C. for 24 hours
  2. customThe reaction mixture was quenched with water
  3. extractionfollowed by an extraction with ethylacetate
  4. customRemoval of organic solvents
  5. customin vacuo and purification by HPLC
  6. customprovided compound A63 as a white solid

출처 및 근거

ORD 기록
ord-9cfc3c4921f04b65bea4efcb33d011c8
출처 데이터셋
uspto-grants-2013_04
특허 번호
US08410119B2

연결된 노트

불러오는 중…